ArticleEJHaem2026

Pragmatic Clinical Trial of Fostamatinib as Second-Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial.

Amber Afzal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.